Mauna Kea Technologies S.A. (ALMKT)
XPAR 
Summary
Mauna Kea Technologies S.A. (ALMKT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mauna Kea Technologies S.A. ever had a stock split?
Mauna Kea Technologies S.A. Profile
| Health Care Technology Industry | Healthcare Sector | Mr. Alexandre Loiseau Ph.D. CEO | XPAR Exchange | FR0010609263 ISIN |
| France Country | 61 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Mauna Kea Technologies SA, established in 2000 and headquartering in Paris, France, is a pioneering company in the medical device industry. It has earned a reputation for its extensive contributions to healthcare through its innovative approach in developing and marketing medical devices across Europe and internationally. The company serves an array of specialties, including gastroenterology, pulmonology, urology, and drug development, providing state-of-the-art tools that aid physicians in the diagnosis and treatment of various diseases.
Products and Services
The company's flagship product is the Cellvizio, an advanced cellular imaging platform that marks a significant advancement in medical imaging technology by offering a real-time, in vivo look at cellular structures. This platform offers numerous applications:
- Gastroenterology: In gastroenterology, Cellvizio can be used to visually assess and monitor the health of the gastrointestinal tract, helping in the early detection of abnormalities that may indicate disease.
- Pulmonology: For pulmonology, it allows detailed observation of the lung tissues, aiding in the diagnosis and management of lung diseases and conditions.
- Urology: Within the field of urology, Cellvizio provides valuable insights into the urinary tract and bladder, enabling the detection and assessment of tumors or other anomalies.
- Drug Development: The platform also finds application in drug development processes, offering real-time cellular reactions to pharmaceuticals, which can significantly aid in the development of new treatments and drugs.
Through Cellvizio’s ability to provide detailed and real-time cellular images, physicians are empowered to monitor the progression of diseases over time, assess reactions at particular moments, and guide surgical interventions with greater accuracy than ever before. With its innovative products targeted towards enhancing diagnostic accuracy and improving patient outcomes, Mauna Kea Technologies SA continues to play a crucial role in the advancement of medical sciences.
